Here is the design of a clinical trial:

Official Title: A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition

Included conditions:
- Short Bowel Syndrome
- Malabsorption

Study Armgroups:
- {'label': 'Relizorb treatment', 'type': 'EXPERIMENTAL', 'description': 'Patients will have tube feeds placed through chamber and evaluate wean from parenteral nutrition', 'interventionNames': ['Device: Relizorb']}

Interventions:
- {'type': 'DEVICE', 'name': 'Relizorb', 'description': 'Tube feeds run across device to digest fats.', 'armGroupLabels': ['Relizorb treatment']}

Primary Outcomes:
- {'measure': 'Effectiveness of the RELiZORB enzyme cartridge on the absorption of enteral nutrition based on PN calories', 'description': 'To determine the effectiveness of the RELiZORB enzyme cartridge on the absorption of enteral nutrition when used daily for a total 90 days of treatment, in pediatric subjects with SBS who are PN dependent, aged 2 years - 18 years, by measuring the change in PN calories from baseline, assessed at days 7, 14, 28, 60, and day 90. Each subject will be on the study for a total of 90 days.', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
A two-sided alpha of 0.05 and 80% power were used. The standard deviation (SD) was considered to be 0.14, but a conservative estimate doubled the SD to 0.28. The confidence interval (CI) for a 20% reduction with SD = 0.14 was (0.75, 0.85), and with SD = 0.28 was (0.7, 0.9).
Sample size
          Precision-based power calculations were determined using nQuery Advisor 7.0 (GraphPad Software DBA Statistical Solutions, San Diego, CA). The primary outcome is the change in PN calories from baseline, assessed weekly at 13 assessments (study days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84, and 90) using a baseline-adjusted time-weighted average (AUC7-90). In adults receiving teduglutide intended to improve enteral absorption in PN dependent patients with intestinal failure, an aim of 20% reduction was used to assess efficacy [9]. When adapted for a pediatric intestinal failure population, a â¥10% reduction was considered a valid pharmacodynamics (PD) marker of increased intestinal absorptive capacity. Based on the design of the teduglutide studies it was felt that the data provide similar support for a â¥10% reduction at Day 90 as a predictor of pharmacodynamic effect with the use of the RELiZORB device.
          A reliable estimate for the standard deviation (SD) of AUC7-90 for the primary outcome in this patient population is unavailable. Unpublished data for seven patients are available, but at least four of these would not meet the eligibility criteria for this study (ages 1â10; one had a STEP procedure; three have pancreatic involvement). Nevertheless, the mean Â± SD reduction (AUC7-90) for these seven patients was 0.81Â±0.14, representing a 19% decrease over 90 days. Using this SD with a sample size of n = 32, a 20% observed reduction in outcome would provide a 95% confidence interval (CI) = (0.75, 0.85), ruling out a true mean population reduction smaller than 15%. Conservatively, if the SD was doubled (SD = 0.28), the 95% CI = (0.7, 0.9), excluding a true mean population reduction smaller than 10%, our target threshold. In general, for any continuous outcome, a sample size of n = 32 with two-side alpha = 0.05 will provide 80% power to detect an effect size (mean/SD) as small as 0.51, considered a medium-sized effect [16].